Drug Profile
LY 2124275
Latest Information Update: 24 Mar 2009
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Neuropsychotherapeutics
- Mechanism of Action Adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Mood disorders
Most Recent Events
- 24 Mar 2009 Discontinued - Phase-I for Affective disorders in USA (PO)